External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Leukemia & Lymphoma

Leukemia & Lymphoma

Lymphoma is the most common type of blood cancer, with over 400,000 people diagnosed around the world each year.

It begins in a certain type of cell of the immune system (lymphocytes, or white blood cells) and can be divided into two main categories – Hodgkin lymphoma, and Non-Hodgkin lymphoma (NHL).

NHL is the more common of the two and can be further categorised as indolent (slow growing) or aggressive (fast growing), depending on the speed with which the cancer grows. Follicular lymphoma is the most common indolent form of the disease and diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form.

Leukaemia is the second most common form of blood cancer, with over 300,000 people diagnosed globally each year. The type of leukaemia that a person has is dependent on which type of blood cell – white or red – becomes cancerous.

The four main types of leukaemia include acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), and chronic myeloid leukaemia (CML).

Learn more about the latest advances in Roche lymphoma and leukaemia research.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Jul 4 / Roche and Genentech
Burden of Illness in Patients with Higher-risk Myelodysplastic Syndromes by Baseline Transfusion Status
A retrospective observational study using the SEER-Medicare linked database to better understand the transfusion burden in patients with higher-risk myelodysplastic syndromes at baseline and how this burden is impacted post-HMA initiation, as well as the healthcare resource utilization and costs amongst these patients post-HMA initiation, according to baseline transfusion status.
Haematology Oncology Leukaemia & Lymphoma ASH-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jul 7 / Roche and Genentech
Clinical Evaluation of Somatic Genomic Alteration Annotation for Hematological Malignancies using NAVIFY® Tertiary Analysis Software
The NAVIFY® Mutation Profiler is a CE-marked, cloud-based tertiary analysis software that provides curation, annotation, and reporting of somatic genomic alterations and biomarker signatures identified by NGS (next-generation sequencing). This poster shows the results of a clinical evaluation study validating the accuracy and reproducibility of the NMP software and curation process across a panel of hematologic malignancies.
Haematology Acute Lymphocytic Leukemia Leukaemia & Lymphoma Diffuse Large B-Cell Lymphoma Acute Myeloid Leukaemia Chronic Lymphocytic Leukaemia Follicular Lymphoma Multiple Myeloma AACR-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 11 / Roche and Genentech
Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study
GALLIUM is a Phase III, randomized study of obinutuzumab-based immunochemotherapy versus rituximab-based immunochemotherapy in patients with previously untreated advanced indolent non-Hodgkin lymphoma. Here we report the results of the final analysis in patients with follicular lymphoma after eight years of follow-up.
Haematology Oncology Follicular Lymphoma Relapsed Refractory Non Hodgkin Lymphoma Non Hodgkin Lymphoma Leukaemia & Lymphoma EHA-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 10 / Roche and Genentech
Clinical outcomes in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: A large population-based analysis
A large population-based analysis, using the SEER-Medicare linked database, to understand the survival outcomes and progression-related events of older patients (aged ≥66 years) treated with azacitidine or decitabine for higher-risk-MDS in the USA.
Haematology Oncology Leukaemia & Lymphoma EHA-2022

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Jan 7 / Springer Healthcare
ASH 2021 In-Depth Report: Lymphoma
This ASH 2021 in-depth report provides an update on recent advances in the management of aggressive and indolent lymphomas.
Haematology Leukaemia & Lymphoma ASH-2021
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Jan 7 / Springer Healthcare
ASH 2021 In-Depth Report: Leukaemia
This ASH 2021 in-depth report provides an overview of the aetiology and treatment of leukaemia.
Haematology Leukaemia & Lymphoma Immunotherapy ASH-2021
Bookmark this
Share page
Upcoming Congresses
Access to Roche and Genentech's medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.